Generate Biomedicines, Inc. (GENB) Revenue, Earnings & Financial Statements
Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)
Generate Biomedicines, Inc. most recently reported annual revenue of $32.0M, a net loss of $203.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Generate Biomedicines, Inc.: Revenue rose from $20.0M in 2024 to $32.0M in 2025, a change of +60.0% over 1 year; operating margin moved from -962.6% to -737.0%, a shift of +225.6 percentage points; the most recent year shows a net loss of $203.0M.
Income Statement — 2 Years (USD millions)
Quarterly Results — Last 5 Quarters (USD millions)
Over the 2 years reported for Generate Biomedicines, Inc., borrowings decreased from $77.0M in 2024 to $69.0M in 2025, cash stood at $122.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 2.85 times.
Balance Sheet — 2 Years (USD millions)
For Generate Biomedicines, Inc., free cash flow in the latest year was negative at $204.0M.
Cash Flow Statement — 2 Years (USD millions)
Valuation & Return Ratios
Generate Biomedicines, Inc. (GENB) financials — frequently asked questions
What is Generate Biomedicines, Inc.'s annual revenue?
Generate Biomedicines, Inc. (GENB) reported annual revenue of $32.0M in its most recent fiscal year.
What is Generate Biomedicines, Inc.'s net profit?
Generate Biomedicines, Inc. (GENB) reported a net loss of $203.0M in its most recent fiscal year.
What is GENB EV/EBITDA?
Generate Biomedicines, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -9.33. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.
Revenue and earnings of other Biotechnology stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.